FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4286293846> ?p ?o ?g. }

• W4286293846 endingPage "e13034" @default.
• W4286293846 startingPage "e13034" @default.
• W4286293846 abstract "e13034 Background: HR-positive, Her2-negative metastatic breast cancer patients harboring PIK3CA mutations are associated with resistance to endocrine therapy and worse prognosis. Results from the phase III SOLAR-1 trial demonstrate improved PFS for patients treated with Alpelisib-Fulvestrant after failure on first or second line treatment with aromatase inhibitor. Methods: Within an early access program for Alpelisib in a single oncology center, patients diagnosed with metastatic HR-positive, Her2 -negative breast cancer were screened for PIK3CA mutations. New generation sequencing (NGS) was the preferred technique to identify carriers with PIK3CA mutations on soft tissue or liquid biopsy. Patients who progressed and carried PIK3CA mutations received Alpelisib and fulvestrant as subsequent line of therapy. Results: Among 32 patients (pts) screened, 13 (40,6%) had a PIK3CA mutation. In total, 11 pts received alpelisib. Median age at diagnosis was 57.5 years (range, 39-69). Eight pts (72.7%) had been operated for early-stage breast cancer, 6 (54.5%) had received adjuvant chemotherapy and 5 (45.5%) had received adjuvant radiotherapy. Of 11 pts with evaluable histology, 3 pts (27.3%) had high grade tumors at diagnosis. Ten pts (90.9%) had PR positive tumors. Median Ki67 was 20% (range, 2-80). Eight pts (72.7%) had PIK3CA exon 20 and 3 (27.3%) had exon 9 mutations. Six pts (54.5%) had received prior chemotherapy in the metastatic setting and 10 (90.9%) prior CDK4/6 inhibitor. Three pts (27.3%) received Alpelisib as 2 nd line and all remaining patients received alpelisib beyond 3 rd line treatment. All pts (100%) had metastasis to the bones, 8 pts (72.7%) to the liver, 6 pts (54.5%) to the lungs and 2 pts (18.2%) to the brain. Until the date of last assessment, Alpelisib was administered for a median of 5.1 months (range, 0.4-21.3). Ten pts were evaluable for response to treatment with Alpelisib. One (10%) had CR, 5 (50%) SD and 4 (40%) PD as best response. Median duration of disease control was not reached. Baseline characteristics were not associated with disease control. Adverse events noticed were thrombocytopenia grade II (1/11), diarrhea grade II (2/11), skin rash grade I &II (4/11), weakness grade III (1/11) and hyperglycemia (3/11). Conclusions: Prevalence of PIK3CA mutations is consistent with published data. Furthermore, combination of Alpelisib-Fulvestrant is a highly active line of therapy even in heavily pretreated patients." @default.
• W4286293846 created "2022-07-21" @default.
• W4286293846 creator A5016114951 @default.
• W4286293846 creator A5020791038 @default.
• W4286293846 creator A5027934270 @default.
• W4286293846 creator A5029704952 @default.
• W4286293846 creator A5064250542 @default.
• W4286293846 creator A5070020579 @default.
• W4286293846 creator A5070188844 @default.
• W4286293846 creator A5080509334 @default.
• W4286293846 creator A5081883510 @default.
• W4286293846 date "2022-06-01" @default.
• W4286293846 modified "2023-09-27" @default.
• W4286293846 title "Single center experience with alpelisib-fulvestrant in heavily pretreated women with HR(+), HER-2 (−) metastatic breast cancer." @default.
• W4286293846 doi "https://doi.org/10.1200/jco.2022.40.16_suppl.e13034" @default.
• W4286293846 hasPublicationYear "2022" @default.
• W4286293846 type Work @default.
• W4286293846 citedByCount "0" @default.
• W4286293846 crossrefType "journal-article" @default.
• W4286293846 hasAuthorship W4286293846A5016114951 @default.
• W4286293846 hasAuthorship W4286293846A5020791038 @default.
• W4286293846 hasAuthorship W4286293846A5027934270 @default.
• W4286293846 hasAuthorship W4286293846A5029704952 @default.
• W4286293846 hasAuthorship W4286293846A5064250542 @default.
• W4286293846 hasAuthorship W4286293846A5070020579 @default.
• W4286293846 hasAuthorship W4286293846A5070188844 @default.
• W4286293846 hasAuthorship W4286293846A5080509334 @default.
• W4286293846 hasAuthorship W4286293846A5081883510 @default.
• W4286293846 hasConcept C121608353 @default.
• W4286293846 hasConcept C126322002 @default.
• W4286293846 hasConcept C143998085 @default.
• W4286293846 hasConcept C2775930923 @default.
• W4286293846 hasConcept C2776215463 @default.
• W4286293846 hasConcept C2776694085 @default.
• W4286293846 hasConcept C2777176818 @default.
• W4286293846 hasConcept C2778504769 @default.
• W4286293846 hasConcept C2780073493 @default.
• W4286293846 hasConcept C2780482068 @default.
• W4286293846 hasConcept C530470458 @default.
• W4286293846 hasConcept C71924100 @default.
• W4286293846 hasConceptScore W4286293846C121608353 @default.
• W4286293846 hasConceptScore W4286293846C126322002 @default.
• W4286293846 hasConceptScore W4286293846C143998085 @default.
• W4286293846 hasConceptScore W4286293846C2775930923 @default.
• W4286293846 hasConceptScore W4286293846C2776215463 @default.
• W4286293846 hasConceptScore W4286293846C2776694085 @default.
• W4286293846 hasConceptScore W4286293846C2777176818 @default.
• W4286293846 hasConceptScore W4286293846C2778504769 @default.
• W4286293846 hasConceptScore W4286293846C2780073493 @default.
• W4286293846 hasConceptScore W4286293846C2780482068 @default.
• W4286293846 hasConceptScore W4286293846C530470458 @default.
• W4286293846 hasConceptScore W4286293846C71924100 @default.
• W4286293846 hasIssue "16_suppl" @default.
• W4286293846 hasLocation W42862938461 @default.
• W4286293846 hasOpenAccess W4286293846 @default.
• W4286293846 hasPrimaryLocation W42862938461 @default.
• W4286293846 hasRelatedWork W1901834169 @default.
• W4286293846 hasRelatedWork W2060548158 @default.
• W4286293846 hasRelatedWork W2087683876 @default.
• W4286293846 hasRelatedWork W2100085165 @default.
• W4286293846 hasRelatedWork W2153169044 @default.
• W4286293846 hasRelatedWork W2292433415 @default.
• W4286293846 hasRelatedWork W2690569173 @default.
• W4286293846 hasRelatedWork W2747078758 @default.
• W4286293846 hasRelatedWork W3004458066 @default.
• W4286293846 hasRelatedWork W3202689974 @default.
• W4286293846 hasVolume "40" @default.
• W4286293846 isParatext "false" @default.
• W4286293846 isRetracted "false" @default.
• W4286293846 workType "article" @default.